New Merck Med...

 

Merck has a new drug med coming this May.  IDVYNSO is a combination of doravirine & islatravir.  It is not recommended for people currently on some meds, such as lamivudine.   It could lower the med's effectiveness & cause possible toxicity.  It's unclear how long a person would have to off lamivudine before they could start this.  This is the only non-INSTI 2 drug med without tenofovir given orally currently available.  

This could be a great new option for people.  These are newer meds comprising a new combo.  Islatravir is the only med in a new category of NRTTIs.  This a significant step.  

Give this piece a read.

Take care.

Cya...

Weekly Pill...

 

Lots of links coming here.  This article & this prior piece, discuss a 2 drug combination medication from Merck & Gilead.  Their drugs, Islatravir & Lencapavir have been combined into a single, weekly dose, oral medication.  These studies show some of the progress & efficacy of the research.  With both meds already having governmental approval, this should be just to prove the viability of the approach.  This could be an option for HIV+ people in the near future.  Personally, I'd opt for the weekly pill over the weekly injection.  

This morning has been rough.  I woke to 70° & it felt hot.  Add to that, wind & allergies are an issue.  My body wasn't ready for this & soon it'll be back to seasonal temps.  

We're trying to get our holiday plans in order.  It'd be nice if the worked.  Things seldom go as planned for us.  But we try.

That's all for now, take care.

Cya...

Dark, Who Knows & Maybes...

 

It's still & wet.  More rain is expected, great, more grass & bugs.  We may not need the AC any more this month, possibly this year.  

The car is still in the shop.  They haven't figured out the issue.  If they don't, it's a waiting game with the car. That sucks.

I found a suggestion of an article.  It's at best midway to a novel approach.  The piece is about PrEP's efficacy.  The current  versions are effective, but only if the regimen is maintained properly.  There are a lot of reasons that may not happen.  The only long acting PrEP options are injections that must be administered by a medical profession.  That may not be an option.   

This work talks about a new antiretroviral from Merck.  This is still an oral option, but has the advantage of being long acting, monthly dose.  This med is based on a Nucleoside reverse transcriptase translocation inhibitor called Islatravir.  So far, this is in the development & research phase.  Human studies are underway.  A monthly dose PrEP could be a game changer.  It could lead to options for people living with HIV as well.

That's all for now, take care.

Cya...